KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. PMID 40774423 · Contemp Clin Trials · 2025-Sep 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany. PMID 40774272 · Lancet Psychiatry · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. PMID 40774040 · Lung Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. PMID 40773982 · Oral Oncol · 2025-Sep The record is a pilot randomized controlled trial for a lymphedema and fibrosis self-management program in head and neck cancer survivors. It is oncology and human, and it is randomized. However, it fails multiple key eligibility criteria: it is a pilot study (not definitive Phase III/IIIb or Phase II/III), it does not involve a drug intervention, and it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. PMID 40763418 · Gynecol Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT). PMID 40763415 · Lung Cancer · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A systematic review of the efficacy of cancer vaccines in advanced breast cancer. PMID 40762664 · Breast Cancer · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial. PMID 40759025 · Ann Intern Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. PMID 40752730 · Actas Urol Esp (Engl Ed) · 2025-Sep The record is a protocol for a Phase III randomized trial with a drug intervention and a time-to-event endpoint, but it does not report formal results. It is excluded as a protocol without results.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. PMID 40752515 · Lancet Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy. PMID 40752049 · Maturitas · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Description of a cruciferous vegetable intervention trial to test the efficacy of a maintenance component to reduce bladder cancer recurrence and progression. PMID 40750073 · Contemp Clin Trials · 2025-Sep The record is a protocol for a randomized controlled trial testing a dietary intervention for bladder cancer. It is not a report of results, does not involve a drug intervention, and does not assess a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial. PMID 40746973 · Lancet Reg Health Southeast Asia · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
[Anti-CD19 treatment: the new gold standard for IgG4-related diseases]. PMID 40745228 · Z Rheumatol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. PMID 40743487 · Neurol Neuroimmunol Neuroinflamm · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement. PMID 40741226 · J Pediatr Clin Pract · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Short-term outcomes of nonintubated and intubated video-assisted thoracoscopic surgery in management of malignant pleural effusion. PMID 40739892 · Asian Cardiovasc Thorac Ann · 2025-Sep The record describes a randomized comparison of two procedural techniques (nonintubated vs intubated VATS) for managing malignant pleural effusion. It does not involve a drug-containing intervention (the intervention is surgical technique with anesthesia type). The primary endpoints are short-term postoperative outcomes (pain scores, dyspnea, radiographic findings), not time-to-event efficacy endpoints like OS, PFS, DFS, etc., and no Kaplan-Meier survival curves or hazard ratios are reported. Therefore, it fails two key eligibility criteria: drug intervention and time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials. PMID 40736113 · Liver Int · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. PMID 40728772 · Am J Clin Dermatol · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial. PMID 40720835 · Ann Intern Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. PMID 40717455 · Aliment Pharmacol Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effects of Vunakizumab Treatment on Detailed Dimensions of Patient-Reported Outcomes in Moderate-to-Severe Plaque Psoriasis Patients: A Post-Hoc Analysis of a Randomized Controlled Trial (NCT04839016). PMID 40713422 · Clin Ther · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome. PMID 40706406 · Atherosclerosis · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. PMID 40700852 · Gynecol Oncol · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized confirmed 2 Figure · 3 Panel · risk visible
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials. PMID 40696240 · Dermatol Ther (Heidelb) · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Enhanced recovery after surgery programs versus conventional rehabilitation for patients undergoing thoracoscopic radical resection of lung cancer in local regional hospitals: a prospective randomized controlled trial. PMID 40696211 · Surg Endosc · 2025-Sep Eligible as a randomized, human, oncology trial with primary results, but excluded because the intervention is non-drug-only (comparing rehabilitation programs, not a drug) and no time-to-event endpoint is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials. PMID 40687731 · Clin Transl Radiat Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial. PMID 40683298 · Lancet Respir Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1. PMID 40677091 · Diabetes Obes Metab · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis. PMID 40676461 · Dermatol Ther (Heidelb) · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The 2018 World Cancer Research Fund/American Institute for Cancer Research Score and Cancer Risk: results from the diabetes prevention program outcomes study. PMID 40675492 · Am J Clin Nutr · 2025-Sep The study is a secondary analysis of a randomized trial (lifestyle vs. metformin vs. placebo for diabetes prevention) examining the association between a lifestyle score and cancer incidence. It meets oncology, human, randomized, and time-to-event criteria, but fails the drug intervention and phase3_or_definitive criteria because the analyzed exposure is a lifestyle score, not a drug, and the oncology analysis is not a definitive trial of a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors. PMID 40674256 · Haemophilia · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial. PMID 40671612 · J Dermatol · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Individual-level analysis of the efficacy of albendazole and albendazole-ivermectin fixed-dose coformulation (FDC) against Trichuris trichiura and hookworms. PMID 40669531 · Acta Trop · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. PMID 40668865 · Am J Respir Crit Care Med · 2025-Sep The study analyzes fluid resuscitation strategies in sepsis, a non-oncology condition, and does not involve a drug intervention or meet oncology-specific criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. PMID 40668079 · Aliment Pharmacol Ther · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2). PMID 40658277 · Dermatol Ther (Heidelb) · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rationale and design of the IMProving Adherence to medications for breast Cancer and cardiovascular disease equiTably (IMPACT) randomized clinical trial. PMID 40653311 · Contemp Clin Trials · 2025-Sep The record is a protocol for a randomized trial in breast cancer patients, but it is not a report of results. The stated outcomes (medication adherence at 28/52 weeks, CVD risk factor control) are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial. PMID 40652952 · Lancet Respir Med · 2025-Sep The record describes a randomized, double-blind, placebo-controlled trial of adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in immunocompromised, HIV-negative patients. It is not an oncology trial focused on a malignant neoplasm. Furthermore, the primary efficacy endpoint is 28-day mortality, which is a binary, fixed-time-point outcome, not a time-to-event endpoint (e.g., OS, PFS) amenable to Kaplan-Meier analysis or hazard ratio reporting. The trial phase is not specified in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial. PMID 40651596 · Radiother Oncol · 2025-Sep Excluded because it is a quality-of-life analysis without a primary/key secondary time-to-event efficacy endpoint and lacks a drug-containing intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study. PMID 40650708 · Adv Ther · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial. PMID 40650707 · Adv Ther · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rationale and design of a race-conscious, school-linked, pilot randomized controlled trial to improve physical activity and dietary behaviors of Black adolescent daughter/mother dyads. PMID 40645370 · Contemp Clin Trials · 2025-Sep 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: A systematic review and network meta-analysis of randomized phase III trials. PMID 40645358 · Crit Rev Oncol Hematol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. PMID 40644648 · J Clin Oncol · 2025-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group's (DBCG) NAME-trial. PMID 40643775 · Breast Cancer Res Treat · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial. PMID 40639764 · Radiother Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study. PMID 40638018 · Gastric Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Concordance of molecular microbiology and conventional culture techniques for infected diabetic foot ulcer management. PMID 40634121 · Diabet Med · 2025-Sep 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results. PMID 40632415 · Gastric Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -